Deutsche Bank AG Increases Stock Position in CME Group Inc. (NASDAQ:CME)

Deutsche Bank AG boosted its position in shares of CME Group Inc. (NASDAQ:CMEFree Report) by 4.3% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,118,104 shares of the financial services provider’s stock after purchasing an additional 46,021 shares during the period. Deutsche Bank AG owned approximately 0.31% of CME Group worth $223,867,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Power Corp of Canada purchased a new position in CME Group during the 1st quarter worth $26,000. OFI Invest Asset Management acquired a new position in shares of CME Group during the third quarter valued at $25,000. MayTech Global Investments LLC bought a new stake in CME Group in the fourth quarter worth about $25,000. Covestor Ltd raised its holdings in CME Group by 65.7% during the 1st quarter. Covestor Ltd now owns 169 shares of the financial services provider’s stock worth $40,000 after buying an additional 67 shares during the period. Finally, Compagnie Lombard Odier SCmA purchased a new position in CME Group during the 3rd quarter valued at about $37,000. 85.69% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other CME Group news, insider Derek Sammann sold 10,681 shares of the firm’s stock in a transaction on Friday, December 1st. The stock was sold at an average price of $220.50, for a total transaction of $2,355,160.50. Following the completion of the sale, the insider now owns 1,862 shares of the company’s stock, valued at $410,571. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other CME Group news, insider Derek Sammann sold 10,681 shares of CME Group stock in a transaction that occurred on Friday, December 1st. The stock was sold at an average price of $220.50, for a total value of $2,355,160.50. Following the sale, the insider now owns 1,862 shares of the company’s stock, valued at approximately $410,571. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Bryan T. Durkin sold 5,560 shares of the company’s stock in a transaction that occurred on Monday, December 11th. The shares were sold at an average price of $216.37, for a total value of $1,203,017.20. Following the completion of the sale, the director now directly owns 62,452 shares in the company, valued at approximately $13,512,739.24. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 18,103 shares of company stock worth $3,971,672. 0.30% of the stock is owned by corporate insiders.

CME Group Stock Performance

Shares of NASDAQ:CME opened at $205.09 on Monday. The firm has a market cap of $73.83 billion, a PE ratio of 24.47, a price-to-earnings-growth ratio of 2.37 and a beta of 0.48. The firm’s 50 day simple moving average is $207.00 and its 200-day simple moving average is $207.92. The company has a debt-to-equity ratio of 0.12, a quick ratio of 1.03 and a current ratio of 1.03. CME Group Inc. has a one year low of $174.01 and a one year high of $223.80.

CME Group Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 26th. Shareholders of record on Friday, March 8th will be given a dividend of $1.15 per share. The ex-dividend date of this dividend is Thursday, March 7th. This represents a $4.60 dividend on an annualized basis and a yield of 2.24%. This is an increase from CME Group’s previous quarterly dividend of $1.10. CME Group’s dividend payout ratio is currently 52.51%.

Analyst Ratings Changes

A number of brokerages recently commented on CME. Rosenblatt Securities restated a “sell” rating and issued a $180.00 target price on shares of CME Group in a research note on Thursday, January 4th. The Goldman Sachs Group lowered CME Group from a “neutral” rating to a “sell” rating and set a $195.00 price target on the stock. in a research report on Wednesday, January 3rd. Morgan Stanley boosted their target price on CME Group from $215.00 to $220.00 and gave the company an “equal weight” rating in a research note on Thursday, October 26th. Finally, Barclays downgraded CME Group from an “overweight” rating to an “equal weight” rating and reduced their price target for the company from $244.00 to $222.00 in a research note on Monday, January 8th. Two investment analysts have rated the stock with a sell rating, five have issued a hold rating and three have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $213.89.

Check Out Our Latest Stock Report on CME

CME Group Profile

(Free Report)

CME Group Inc, together with its subsidiaries, operates contract markets for the trading of futures and options on futures contracts worldwide. It offers futures and options products based on interest rates, equity indexes, foreign exchange, agricultural commodities, energy, and metals, as well as fixed income and foreign currency trading services.

Read More

Want to see what other hedge funds are holding CME? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CME Group Inc. (NASDAQ:CMEFree Report).

Institutional Ownership by Quarter for CME Group (NASDAQ:CME)

Receive News & Ratings for CME Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CME Group and related companies with MarketBeat.com's FREE daily email newsletter.